Drug Trial Radar · NCT03823300
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
658
Actual
Start
Mar 11, 2019
Primary completion
Oct 5, 2020
Study completion Jan 7, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
Conditions
- Wet Macular Degeneration
Interventions
FaricimabDrug
Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
AfliberceptDrug
Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
Sham ProcedureProcedure
The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48Time frame: From Baseline through Week 48
Locations
137 sites in 21 countries. Site status is shown where the registry gives one.
Associated Retina Consultants
Phoenix, Arizona
Arizona Retina and Vitreous Consultants
Phoenix, Arizona
Northern California Retina Vitreous Associates
Mountain View, California
Retinal Consultants Med Group
Sacramento, California
Orange County Retina Med Group
Santa Ana, California
California Retina Consultants
Santa Barbara, California
Colorado Retina Associates, PC
Golden, Colorado
Retina Group of Florida
Fort Lauderdale, Florida
Retina Care Specialists
Palm Beach Gardens, Florida
Southern Vitreoretinal Assoc
Tallahassee, Florida
Retina Associates of Florida, LLC
Tampa, Florida
Southeast Retina Center
Augusta, Georgia
Georgia Retina PC
Marietta, Georgia
Retina Consultants of Hawaii
‘Aiea, Hawaii
University Retina and Macula Associates, PC
Oak Forest, Illinois
Prairie Retina Center
Springfield, Illinois
Raj K. Maturi, MD PC
Indianapolis, Indiana
Wolfe Eye Clinic
West Des Moines, Iowa
Maine Eye Center
Portland, Maine
The Retina Care Center
Baltimore, Maryland
Cumberland Valley Retina PC
Hagerstown, Maryland
Retina Specialists
Towson, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
VitreoRetinal Surgery, PLLC.
Minneapolis, Minnesota
Mid Atlantic Retina - Wills Eye Hospital
Cherry Hill, New Jersey
Island Retina
Shirley, New York
Retina Assoc of Cleveland Inc
Cleveland, Ohio
The Ohio State University Havener Eye Institute
Columbus, Ohio
Midwest Retina
Dublin, Ohio
Palmetto Retina Center
West Columbia, South Carolina
Southeastern Retina Associates Chattanooga
Chattanooga, Tennessee
Retina Res Institute of Texas
Abilene, Texas
Austin Retina Associates
Austin, Texas
Austin Clinical Research LLC
Austin, Texas
Retina Center of Texas
Grapevine, Texas
Retina Consultants of Houston
The Woodlands, Texas
Strategic Clinical Research Group, LLC
Willow Park, Texas
Retina Associates of Utah, PLLC
Murray, Utah
Piedmont Eye Center
Lynchburg, Virginia
Wagner Kapoor Institute
Norfolk, Virginia
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.